Due to the high incidence and mortality associated with NSCLC, the early precise determination of some of the most common somatic mutations, such as EGFR mutational status, will be beneficial in improving lesion differentiation, responses to predictions and evaluations, and prognostication (7–9). This evidence concerns the gene EGFR and non-small cell lung carcinoma.